Impact Factor 4.137 | CiteScore 4.28
More on impact ›
Pharmacology of Anti-Cancer Drugs is a specialty section of Frontiers in Pharmacology and Frontiers in Oncology.
Prospective authors, please note:
Specific requirements are detailed for the conception and review of manuscripts - characterization of pharmacological agents, selectivity for cancer cells, and demonstration of effects in multiple cell lines - at the below link.
This section on Pharmacology of Anti-Cancer Drugs is devoted to the publication of high quality research concerning all aspects of cancer and benign neoplasm drug treatment. The scope of the specialty section encompasses studies related to drugs targeting tumor cells, but also the various components of the tumor microenvironment, including non-tumor cells (e.g., endothelial cells, macrophages, lymphocytes, and fibroblasts), and stress conditions such as hypoxia and acidity. Relevant to the specialty section is experimental, pre-clinical or clinical research addressing the potential and limitations of new antineoplastic and antimetastatic therapies issued from inventive drug design or bioguided isolation from plants. Cancer treatment is an area of medicine where the concepts of multi-modality, drug delivery, and personalized medicine are the most advanced. Therefore, Pharmacology of Anti-Cancer Drugs will also have a particular interest in the following issues: The synergy between chemotherapy and other anticancer modalities, including radio-, immuno- and gene therapy; the use of nanoscale particles or targeting moieties to improve drug bioavailability; and the identification of biomarkers derived from proteomics, and genomics or imaging technologies to predict response or resistance to drug treatment.
Guidelines for the conception/peer-review of submissions
As many anticancer drugs working as cytotoxic compounds have non-selective effects annihilating their potential therapeutic benefits, manuscripts are advised to provide evidence of a significant selectivity towards cancer cells (vs. healthy cells). Specifically, if the studied anticancer drug or modality does not target an oncogenic pathway, the authors should make every effort possible to prove that the cytotoxic or cytostatic effects they have identified exhibit selectivity for cancer cells (ideally 1 log difference in EC50 or IC50) vs. non-malignant cells (eg, fibroblasts or primary culture of cells).
The authors should also demonstrate the applicability of their anticancer modalities on a minimum of two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues).
In addition, for manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included.
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Pharmacology of Anti-Cancer Drugs welcomes submissions of the following article types: Case Report, Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Pharmacology of Anti-Cancer Drugs, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Pharmacology of Anti-Cancer Drugs will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology and Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org